Penpulimab in combination therapy for the first-line treatment of metastatic NPC, has had its marketing application accepted by the NMPA and the FDA. Additionally, the marketing application for its ...
Calidi Biotherapeutics, Inc. recently disclosed information revealing the latest advancements in its targeted antitumor virotherapies. The company’s press release, titled “Calidi Biotherapeutics ...